Gritstone Bio Return on Tangible Equity 2017-2024 | GRTSQ
Current and historical return on tangible equity values for Gritstone Bio (GRTSQ) over the last 10 years. Return on tangible equity can be defined as the amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity.
| Gritstone Bio Return On Tangible Equity Historical Data |
| Date |
TTM Net Income |
Tangible Equity |
Return on Tangible Equity |
| 2024-06-30 |
$-0.13B |
$0.02B |
-325.93% |
| 2024-03-31 |
$-0.14B |
$0.01B |
-230.40% |
| 2023-12-31 |
$-0.14B |
$0.05B |
-146.42% |
| 2023-09-30 |
$-0.14B |
$0.07B |
-111.29% |
| 2023-06-30 |
$-0.13B |
$0.11B |
-93.02% |
| 2023-03-31 |
$-0.13B |
$0.14B |
-81.70% |
| 2022-12-31 |
$-0.12B |
$0.17B |
-72.73% |
| 2022-09-30 |
$-0.12B |
$0.14B |
-67.52% |
| 2022-06-30 |
$-0.12B |
$0.16B |
-60.31% |
| 2022-03-31 |
$-0.11B |
$0.19B |
-56.57% |
| 2021-12-31 |
$-0.08B |
$0.22B |
-37.41% |
| 2021-09-30 |
$-0.07B |
$0.21B |
-38.25% |
| 2021-06-30 |
$-0.07B |
$0.18B |
-45.38% |
| 2021-03-31 |
$-0.07B |
$0.20B |
-53.18% |
| 2020-12-31 |
$-0.11B |
$0.17B |
-93.33% |
| 2020-09-30 |
$-0.11B |
$0.07B |
-101.68% |
| 2020-06-30 |
$-0.11B |
$0.10B |
-86.23% |
| 2020-03-31 |
$-0.10B |
$0.12B |
-70.19% |
| 2019-12-31 |
$-0.10B |
$0.13B |
-62.91% |
| 2019-09-30 |
$-0.08B |
$0.16B |
-54.28% |
| 2019-06-30 |
$-0.08B |
$0.18B |
-55.97% |
| 2019-03-31 |
$-0.07B |
$0.13B |
-77.97% |
| 2018-12-31 |
$-0.06B |
$0.15B |
-115.32% |
| 2018-06-30 |
$-0.04B |
|
inf% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-BIOMED/GENE |
$0.000B |
$0.016B |
|
Gritstone Oncology is developing tumor-specific cancer immunotherapies to fight multiple cancer types. The company has built its tumor-specific immunotherapy approach on two key pillars - first, a proprietary machine learning-based platform, Gritstone EDGE(TM), which provides a powerful ability to predict from a routine tumor biopsy the tumor-specific neoantigens, or TSNA, that are presented on a patient?s tumor cells; and second, the ability to develop and manufacture potent immunotherapies utilizing patients? TSNA to drive the patient?s immune system to attack and destroy tumors.
|
